Boston Scientific to Acquire Nalu Medical - Gilde Healthcare

Menu
Menu
Home

Boston Scientific to Acquire Nalu Medical

Geoff Pardo

General Partner Healthtech
Venture&Growth
United States of America

Karthik Bolisetty

Investment Manager Healthtech
Venture&Growth
United States of America
October 17, 2025
Utrecht (the Netherlands) & Boston, MA (United States)

We are pleased to announce the strategic exit of our portfolio company Nalu Medical. Boston Scientific, a global leader in medical technology, has agreed to acquire Gilde Healthcare portfolio company Nalu Medical at a $600m valuation.

Nalu Medical markets a miniaturized implantable neurostimulation device to treat patients with chronic neuropathic pain.
Boston Scientific expects to complete the transaction in the first half of 2026, subject to customary closing conditions.

Gilde Healthcare co led the $104m financing round in 2022 and Geoff Pardo serves on the Board of Directors.

Press Release

More news

Hermann Medizintechnik joins SPI – the specialized MedTech CDMO platform sponsored by Gilde Healthcare

Hermann Medizintechnik ("Hermann") has officially joined Gilde Healthcare's group of contract manufacturers for complex surgical instruments and implants ("SPI"), marking another significant milestone for SPI. With Hermann, SPI grows to more than 500 highly skilled...
September 10, 2026

BENTEC Endoscopy joins Gilde Healthcare’s contract manufacturing group for surgical instruments and implants

Gilde Healthcare's group of contract manufacturers for complex surgical instruments and implants ("SPI") is acquiring BENTEC Endoscopy ("BENTEC"). The transaction marks another significant milestone in building a leading group for the contract manufacturing of surgical...
August 27, 2026

Gilde Healthcare company Amphista Therapeutics announces FDA clearance of IND application for AMX-883, its lead Targeted Glue™ degrader for acute myeloid leukaemia

Amphista to initiate its first clinical trial for AMX-883, a potent, orally bioavailable DCAF16-dependent degrader of BRD9, for acute myeloid leukaemia (AML) in H2 2026 The Phase 1 monotherapy dose-escalation and optimisation trial will enrol...
June 11, 2026